Stuart

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9597536/publications.pdf

Version: 2024-02-01

87	5,712	172386 29	85498 71
papers	citations	h-index	g-index

87	87	87	6635
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens. JAMA - Journal of the American Medical Association, 2015, 313, 1122.	3.8	499
2	Outcome at 8 Years After Breast-Conserving Surgery and Radiation Therapy for Invasive Breast Cancer: Influence of Margin Status and Systemic Therapy on Local Recurrence. Journal of Clinical Oncology, 2000, 18, 1668-1675.	0.8	492
3	Society of Surgical Oncologyâ€“American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 553-564.	0.4	364
4	Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer, 1984, 53, 1049-1057.	2.0	348
5	Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathology, 2010, 23, S60-S64.	2.9	308
6	Loss of Tumor Marker-Immunostaining Intensity on Stored Paraffin Slides of Breast Cancer. Journal of the National Cancer Institute, 1996, 88, 1054-1059.	3.0	273
7	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
8	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2016, 34, 4040-4046.	0.8	211
9	Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy. Nature Biotechnology, 2017, 35, 757-764.	9.4	182
10	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2016, 23, 3801-3810.	0.7	176
11	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. American Journal of Surgical Pathology, 2013, 37, e1-e11.	2.1	137
12	Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia. Cancer, 2007, 109, 180-187.	2.0	136
13	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Practical Radiation Oncology, 2016, 6, 287-295.	1.1	135
14	Results of treating ductal carcinomaIn situ of the breast with conservative surgery and radiation therapy. Cancer, 1991, 67, 7-13.	2.0	122
15	The Spectrum of Triple-Negative Breast Disease. American Journal of Pathology, 2017, 187, 2139-2151.	1.9	118
16	Computational Pathology to Discriminate Benign from Malignant Intraductal Proliferations of the Breast. PLoS ONE, 2014, 9, e114885.	1.1	106
17	IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.4	99
18	Differential immunohistochemical detection of transforming growth factor Î±, amphiregulin and CRIPTO in human normal and malignant breast tissues. , 1996, 65, 51-56.		95

#	Article	IF	Citations
19	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	2.3	90
20	The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. , 2000, 88, 1072-1077.		85
21	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	82
22	Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer, 1998, 83, 2502-2508.	2.0	78
23	The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease. Cancer, 2006, 107, 1240-1247.	2.0	77
24	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1â€“98. Breast Cancer Research, 2019, 21, 30.	2.2	76
25	Benign Breast Disease and Breast Cancer Risk. American Journal of Surgical Pathology, 2003, 27, 836-841.	2.1	74
26	Eâ€cadherin immunohistochemistry in breast pathology: uses and pitfalls. Histopathology, 2016, 68, 57-69.	1.6	64
27	Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma. , 1997, 79, 1362-1369.		59
28	Extensive apoptosis in ductal carcinoma in situ of the breast. , 1996, 77, 1831-1835.		54
29	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncology, 0, , .	3.4	51
30	Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Research and Treatment, 2011, 128, 243-250.	1.1	49
31	Pan-TRK Immunohistochemistry. American Journal of Surgical Pathology, 2019, 43, 1693-1700.	2.1	49
32	Predictors of local recurrence following excision alone for ductal carcinoma in situ. , 1999, 85, 427-431.		40
33	Radial scars and subsequent breast cancer risk: results from the Nursesâ€™ Health Studies. Breast Cancer Research and Treatment, 2013, 139, 277-285.	1.1	40
34	Benign breast disease resolved and unresolved issues. Cancer, 1993, 71, 1187-1189.	2.0	31
35	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Npj Breast Cancer, 2016, 2, 16002.	2.3	31
36	Clinical and Pathologic Features of Breast Cancers in Women Treated for Hodgkin's Disease: A Case-Control Study. Breast Journal, 2001, 7, 46-52.	0.4	30

#	Article	IF	Citations
37	EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nursesâ€™ Health Studies. Breast Cancer Research, 2017, 19, 21.	2.2	29
38	Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue. Npj Breast Cancer, 2017, 3, 39.	2.3	27
39	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. Modern Pathology, 2019, 32, 1257-1262.	2.9	27
40	Local Outcomes in Ductal Carcinoma In Situ Based on Patient and Tumor Characteristics. Journal of the National Cancer Institute Monographs, 2010, 2010, 158-161.	0.9	26
41	Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Caseâ€“Control Study. Annals of Surgical Oncology, 2015, 22, 502-508.	0.7	26
42	Histopathologic findings in breast surgical specimens from patients undergoing female-to-male gender reassignment surgery. Modern Pathology, 2019, 32, 346-353.	2.9	25
43	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 19.	2.3	23
44	American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications. Annals of Diagnostic Pathology, 2020, 45, 151481.	0.6	23
45	Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology. Journal of Pathology Informatics, 2014, 5, 3.	0.8	22
46	Vascular lesions of the breast. Seminars in Diagnostic Pathology, 2017, 34, 410-419.	1.0	22
47	Understanding the distribution of cancer within the breast is important for optimizing breast-conserving treatment. Cancer, 1995, 76, 1-3.	2.0	21
48	Testosterone therapy and breast histopathological features in transgender individuals. Modern Pathology, 2021, 34, 85-94.	2.9	21
49	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	2.3	20
50	Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2019, 26, 3846-3855.	0.7	19
51	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. Modern Pathology, 2020, 33, 1287-1297.	2.9	19
52	Chest wall recurrence of ductal carcinoma in situ of the breast after mastectomy. Cancer, 1993, 71, 3025-3028.	2.0	18
53	Will Molecular Classification Replace Traditional Breast Pathology?. International Journal of Surgical Pathology, 2010, 18, 162-166.	0.4	18
54	Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. Modern Pathology, 2021, 34, 875-882.	2.9	18

#	Article	IF	Citations
55	Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectrum, 2018, 2, pky063.	1.4	17
56	Deep learning assessment of breast terminal duct lobular unit involution: Towards automated prediction of breast cancer risk. PLoS ONE, 2020, 15, e0231653.	1.1	16
57	Craniopharyngioma in an elderly patient. Cancer, 1987, 60, 1077-1080.	2.0	15
58	Evolution of Breast-Conserving Therapy for Localized Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1395-1396.	0.8	14
59	Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Research and Treatment, 2018, 167, 751-759.	1.1	14
60	Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy. Modern Pathology, 2021, 34, 1-7.	2.9	11
61	Deep Learning Image Analysis of Benign Breast Disease to Identify Subsequent Risk of Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa119.	1.4	11
62	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Annals of Oncology, 2022, 33, 234-238.	0.6	11
63	Molecular Biology of Breast Tumor Progression: A View From the Other Side. International Journal of Surgical Pathology, 2010, 18, 170-173.	0.4	10
64	Recurrence of breast carcinoma as Paget disease of the skin at a prior core needle biopsy site: Case report and review of the literature. International Journal of Surgery Case Reports, 2015, 15, 152-156.	0.2	10
65	What to do about mammographically detected ductal carcinoma in situ?. Cancer, 1992, 70, 2576-2578.	2.0	9
66	Clinical and histologic aspects of proliferative and non-proliferative benign breast disease. Journal of Cellular Biochemistry, 1993, 53, 45-48.	1.2	9
67	Spindle Cell Lesions of the Breast. Surgical Pathology Clinics, 2009, 2, 375-390.	0.7	8
68	Problematic issues in breast core needle biopsies. Modern Pathology, 2019, 32, 71-76.	2.9	8
69	Breast carcinomas of low malignant potential. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 5-19.	1.4	8
70	Genotype-Phenotype Correlations in Breast Cancer. Surgical Pathology Clinics, 2018, 11, 199-211.	0.7	7
71	Dilemmas in Breast Disease. Breast Journal, 1998, 4, 204-208.	0.4	5
72	Important Inflammatory and Reactive Lesions of the Breast. Surgical Pathology Clinics, 2012, 5, 567-590.	0.7	5

#	Article	IF	Citations
73	Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Research and Treatment, 2016, 155, 541-549.	1.1	5
74	The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease. Npj Breast Cancer, 2021, 7, 23.	2.3	5
75	Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity. Modern Pathology, 2022, 35, 1370-1382.	2.9	5
76	Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947â€“2009). Npj Breast Cancer, 2015, 1, .	2.3	4
77	Extensive apoptosis in ductal carcinoma in situ of the breast. , 1996, 77, 1831.		2
78	Contemporary issues in breast pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1-3.	1.4	2
79	Reply to Rosen. Modern Pathology, 2017, 30, 1505-1506.	2.9	1
80	Evaluation of margins in invasive carcinoma and ductal carcinoma in situ: The pathologist's perspective. Breast, 2017, 34, S58-S60.	0.9	1
81	Feasibility of analyzing DNA copy number variation in breast cancer tumor specimens from 1950 to 2010: how old is too old?. Cancer Causes and Control, 2018, 29, 305-314.	0.8	1
82	Differential immunohistochemical detection of transforming growth factor Î±, amphiregulin and CRIPTO in human normal and malignant breast tissues. International Journal of Cancer, 1996, 65, 51-56.	2.3	1
83	Results of treating ductal carcinoma In situ of the breast with conservative surgery and radiation therapy. , 1991, 67, 7.		1
84	Impact of residual nodal disease burden on sentinel node mapping and accuracy of intraoperative frozen section in node positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2018, 36, 584-584.	0.8	1
85	Case Selection Does Not Permit Conclusions. American Journal of Clinical Pathology, 1988, 89, 293-293.	0.4	0
86	The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received.. Journal of Clinical Oncology, 2018, 36, 1054-1054.	0.8	0
87	The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation.. Journal of Clinical Oncology, 2020, 38, 581-581.	0.8	0